Pathway Genomics has launched Hereditary Colorectal Cancer DNA Insight, which uses next-generation sequencing to identify genetic alterations that are indicative of a risk for colorectal cancer, including genes related to Lynch syndrome, familial adenomatous polyposis, Li-Fraumeni syndrome, juvenile polyposis, MUTYH-associated polyposis, Peutz-Jeghers syndrome, hereditary diffuse gastric cancer, and PTEN-hamartoma tumor syndrome.
Courtagen Life Sciences has expanded EpiSeek, its next-generation sequencing test for epilepsy and seizure disorders, to include 489 genes associated with seizure disorders. Additionally, the company has also launched an Infancy and Childhood Epilepsy Panel, which targets 70 genes.